In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Commentary|Articles|July 16, 2026
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
Author(s)Chris Ryan
Fact checked by: Riley Kandel
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
At the
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement